FY 2025 report
Hemp & Health zamknęło w 2025 r. strategię budowy łańcucha dostaw medycznej marihuany i sprzedało wszystkie udziały w THC Pharma/Certis Pharma.
Sentiment
Cautious
No guidance change
HMP
FY 2025 report
Revenue
209.14 k PLN
— YoY
Net income
-1,428.77 k PLN
— YoY
EBITDA
-1,339.47 k PLN
— YoY
FCF
-1,537.78 k PLN
— YoY
Summary
Investment thesis
- Spółka nie ma obecnie żadnej istotnej działalności operacyjnej — przychody 209 tys. zł nie pokrywają nawet ułamka kosztów funkcjonowania.
- Bilans jest mały, ale bez długu odsetkowego, z portfelem gotówki i papierów wartościowych jako głównym aktywem.
- Skumulowane straty przewyższyły próg z art. 397 KSH — formalny sygnał ostrzegawczy, choć opinia audytora pozostaje bez zastrzeżeń.
- Przegląd opcji strategicznych uruchomiony w październiku 2025 r. wciąż trwa — bez niego trudno ocenić przyszły profil działalności spółki.
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
HMP · FY 2025
| Metric | FY 2025 | FY 2024 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|
|
Revenue
standalone
|
209.14 | — | — | reported | standalone | 1.00 |
|
EBITDA
standalone
|
-1,339.47 | — | — | derived | standalone | 0.90 |
|
EBIT
standalone
|
-1,442.87 | — | — | reported | standalone | 1.00 |
|
EBT
standalone
|
-1,428.77 | — | — | reported | standalone | 1.00 |
|
Net income
standalone
|
-1,428.77 | — | — | reported | standalone | 1.00 |
|
EPS (basic)
(PLN)
standalone
|
-0.02 | — | — | reported | standalone | 1.00 |
|
D&A
standalone
|
103.4 | — | — | reported | standalone | 1.00 |
|
Interest expense
standalone
|
0 | — | — | reported | standalone | 1.00 |
|
EBITDA margin
standalone
|
-640.43% | — | — | derived | standalone | 0.70 |
|
EBIT margin
standalone
|
-689.66% | — | — | derived | standalone | 0.70 |
|
Net margin
standalone
|
-683.13% | — | — | derived | standalone | 0.70 |
|
Cash
standalone
|
61.83 | — | — | reported | standalone | 1.00 |
|
Total debt
standalone
|
0 | — | — | reported | standalone | 1.00 |
|
Net debt
standalone
|
-61.83 | — | — | derived | standalone | 1.00 |
|
Equity
standalone
|
3,024.67 | — | — | reported | standalone | 1.00 |
|
Total assets
standalone
|
3,189.81 | — | — | reported | standalone | 1.00 |
|
Current assets
standalone
|
1,923.76 | — | — | reported | standalone | 1.00 |
|
Current liabilities
standalone
|
165.14 | — | — | reported | standalone | 1.00 |
|
CFO
standalone
|
-1,474.49 | — | — | reported | standalone | 1.00 |
|
CapEx
standalone
|
63.28 | — | — | reported | standalone | 1.00 |
|
FCF
standalone
|
-1,537.78 | — | — | derived | standalone | 0.90 |
|
ROE
standalone
|
-41.54% | — | — | derived | standalone | 0.80 |
|
ROA
standalone
|
-39.3% | — | — | derived | standalone | 0.80 |
|
ROIC
standalone
|
-48.7% | — | — | derived | standalone | 0.70 |
|
ROCE
standalone
|
-47.69% | — | — | derived | standalone | 0.80 |
|
Current ratio
standalone
|
11.65x | — | — | derived | standalone | 0.90 |
|
Quick ratio
standalone
|
11.65x | — | — | derived | standalone | 0.80 |
|
Cash ratio
standalone
|
0.37x | — | — | derived | standalone | 0.90 |
|
Debt / equity
standalone
|
0x | — | — | derived | standalone | 1.00 |
|
Net debt / equity
standalone
|
-0.02x | — | — | derived | standalone | 0.90 |
|
Revenue growth (YoY)
standalone
|
63.13% | — | — | derived | standalone | 0.90 |
|
EBIT growth (YoY)
standalone
|
-25.02% | — | — | derived | standalone | 0.90 |
|
Net income growth (YoY)
standalone
|
-38.88% | — | — | derived | standalone | 0.90 |
FY 2025 · Δ YoY
Revenue
standalone
209.14
—
standalone
209.14
—
- FY 2024
- —
EBITDA
standalone
-1,339.47
—
standalone
-1,339.47
—
- FY 2024
- —
EBIT
standalone
-1,442.87
—
standalone
-1,442.87
—
- FY 2024
- —
EBT
standalone
-1,428.77
—
standalone
-1,428.77
—
- FY 2024
- —
Net income
standalone
-1,428.77
—
standalone
-1,428.77
—
- FY 2024
- —
EPS (basic)
(PLN)
standalone
-0.02
—
standalone
-0.02
—
- FY 2024
- —
D&A
standalone
103.4
—
standalone
103.4
—
- FY 2024
- —
Interest expense
standalone
0
—
standalone
0
—
- FY 2024
- —
EBITDA margin
standalone
-640.43%
—
standalone
-640.43%
—
- FY 2024
- —
EBIT margin
standalone
-689.66%
—
standalone
-689.66%
—
- FY 2024
- —
Net margin
standalone
-683.13%
—
standalone
-683.13%
—
- FY 2024
- —
Cash
standalone
61.83
—
standalone
61.83
—
- FY 2024
- —
Total debt
standalone
0
—
standalone
0
—
- FY 2024
- —
Net debt
standalone
-61.83
—
standalone
-61.83
—
- FY 2024
- —
Equity
standalone
3,024.67
—
standalone
3,024.67
—
- FY 2024
- —
Total assets
standalone
3,189.81
—
standalone
3,189.81
—
- FY 2024
- —
Current assets
standalone
1,923.76
—
standalone
1,923.76
—
- FY 2024
- —
Current liabilities
standalone
165.14
—
standalone
165.14
—
- FY 2024
- —
CFO
standalone
-1,474.49
—
standalone
-1,474.49
—
- FY 2024
- —
CapEx
standalone
63.28
—
standalone
63.28
—
- FY 2024
- —
FCF
standalone
-1,537.78
—
standalone
-1,537.78
—
- FY 2024
- —
ROE
standalone
-41.54%
—
standalone
-41.54%
—
- FY 2024
- —
ROA
standalone
-39.3%
—
standalone
-39.3%
—
- FY 2024
- —
ROIC
standalone
-48.7%
—
standalone
-48.7%
—
- FY 2024
- —
ROCE
standalone
-47.69%
—
standalone
-47.69%
—
- FY 2024
- —
Current ratio
standalone
11.65x
—
standalone
11.65x
—
- FY 2024
- —
Quick ratio
standalone
11.65x
—
standalone
11.65x
—
- FY 2024
- —
Cash ratio
standalone
0.37x
—
standalone
0.37x
—
- FY 2024
- —
Debt / equity
standalone
0x
—
standalone
0x
—
- FY 2024
- —
Net debt / equity
standalone
-0.02x
—
standalone
-0.02x
—
- FY 2024
- —
Revenue growth (YoY)
standalone
63.13%
—
standalone
63.13%
—
- FY 2024
- —
EBIT growth (YoY)
standalone
-25.02%
—
standalone
-25.02%
—
- FY 2024
- —
Net income growth (YoY)
standalone
-38.88%
—
standalone
-38.88%
—
- FY 2024
- —